Separate Moderna, Novavax efforts focusing on combined COVID-19/flu vaccine
Two separate efforts are underway to provide the public with a combination vaccine that would deliver simultaneous protections against COVID-19 and influenza. Moderna today announced its effort during a research-and-development presentation, in which a vaccine would be encoded for the COVID-19 spike protein and flu hemagglutinin glycoproteins. Novavax yesterday said its own effort, which is in a phase 1/2 clinical trial, combines within a single formulation its recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates with a patented saponin-based adjuvant.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…